Greenwich LifeSciences, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022; financial statements are unaudited. Greenwich is a clinical-stage biopharmaceutical company developing GLSI-100 (GP2 plus GM-CSF), an immunotherapy intended to prevent breast cancer recurrence. It reported no revenue.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $1.72 million | $657,096 | $4.02 million | $1.50 million |
| General and administrative | $659,568 | $209,590 | $1.13 million | $725,130 |
| Total operating expenses | $2.38 million | $866,686 | $5.15 million | $2.22 million |
| Net loss | $2.32 million | $863,118 | $5.03 million | $2.21 million |
| Net loss per share, basic and diluted | $0.18 | $0.07 | $0.39 | $0.17 |
Margins: Not meaningful because the company had no revenue. Cash and liquidity: Cash was $15.64 million at September 30, 2022, versus $27.20 million at December 31, 2021. Nine-month operating cash use was $4.03 million; financing cash use was $7.54 million, principally for repurchases. Total assets were $15.65 million and total liabilities were $237,879, including $220,845 of accounts payable and accrued interest. No material debt balance is reported. Stockholders’ equity was $15.41 million.
Material changes and notable items
- Q3 research and development expense increased 162% year over year; management attributed the increase mainly to stock compensation, clinical, and manufacturing costs. Nine-month R&D expense rose 169%, primarily from cash compensation, clinical, and manufacturing expenses.
- Q3 general and administrative expense rose 215%; the company cited stock compensation and financing expenses. The nine-month increase was 56%, with similar cited drivers.
- During the first nine months, the company used $7.54 million for its stock repurchase program. It repurchased and cancelled approximately 519,828 shares for that aggregate cost by June 30, 2022. The program was authorized for up to $10 million and runs through March 31, 2023, subject to suspension or discontinuation.
- Stock-based compensation was $1.15 million for the first nine months. A June 2022 option grant covering 1,498,128 shares had a stated grant-date fair value of $9.51 million; $653,974 had been expensed through September 30, with the remainder subject to future vesting.
Outlook, risks, and controls
- The company has commenced Flamingo-01, a Phase III trial of GLSI-100. The filing provides no specific financial guidance or trial timeline. Management expects significant expenses and operating losses to continue and says additional capital will be required; future financing is not assured.
- Management reported no material contractual obligations other than employment and shareholder agreements and commitments related to the HJF license, manufacturing, and clinical trials. No off-balance-sheet arrangements or material legal proceedings were reported.
- Disclosure controls and procedures were deemed ineffective at September 30, 2022 due to material weaknesses involving inadequate segregation of duties and insufficient written accounting, IT, financial-reporting, and record-keeping policies. Management said it was developing a remediation plan.
- The filing reported no material changes to the risk factors in the 2021 Form 10-K. The company also noted that results may differ from interim-period results and that forward-looking statements are subject to risks and uncertainty.
Important facts for investors to verify
- Clinical-trial enrollment, execution, timing, and results for Flamingo-01, as well as the regulatory path for GLSI-100.
- Cash use and funding needs relative to available cash, especially as clinical and manufacturing activity expands.
- Whether the company remediates the disclosed internal-control material weaknesses.
- Future stock-based compensation expense and any additional share repurchases or equity financing.
- HJF license, manufacturing, and clinical-trial commitments, including potential milestone and royalty obligations.